627 related articles for article (PubMed ID: 33373866)
21. Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma.
Richmond CS; Vallatharasu Y; Deviley JA; Vos CR; Parsons BM; Kenny PA
Exp Mol Pathol; 2019 Oct; 110():104260. PubMed ID: 31082388
[TBL] [Abstract][Full Text] [Related]
22. Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma.
Lucas P; Boulinguez S; Sibaud V; Mourey L; Lamant L; Paul C; Meyer N
Dermatology; 2018; 234(3-4):92-98. PubMed ID: 30110681
[TBL] [Abstract][Full Text] [Related]
23. Histiocytoid Sweet's syndrome during combined therapy with BRAF and MEK inhibitors for metastatic melanoma.
Morgado-Carrasco D; Moreno-Rivera N; Fustà-Novell X; García-Herrera A; Carrera C; Puig S
Melanoma Res; 2018 Jun; 28(3):256-257. PubMed ID: 29683894
[No Abstract] [Full Text] [Related]
24. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
25. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
26. Advanced Melanoma: Resistance Mechanisms to Current Therapies.
Haugh AM; Salama AKS; Johnson DB
Hematol Oncol Clin North Am; 2021 Feb; 35(1):111-128. PubMed ID: 33759769
[TBL] [Abstract][Full Text] [Related]
27. Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting.
Tétu P; Baroudjian B; Lebbe C
Curr Opin Oncol; 2020 Mar; 32(2):85-90. PubMed ID: 31895121
[TBL] [Abstract][Full Text] [Related]
28. The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors.
Lai-Kwon J; Khoo C; Lo S; Milne D; Mohamed M; Raleigh J; Smith K; Lisy K; Sandhu S; Jefford M
J Cancer Surviv; 2019 Aug; 13(4):503-511. PubMed ID: 31165342
[TBL] [Abstract][Full Text] [Related]
29. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of distant metastasis-free interval in patients with relapsed melanoma treated with BRAF with or without MEK inhibitors.
Bafaloukos D; Papaxoinis G; Linardou H; Diamantopoulos P; Laskarakis A; Anastasopoulou A; Sergentanis TN; Tarampikou A; Tsoutsos D; Gogas H
Melanoma Res; 2019 Aug; 29(4):428-434. PubMed ID: 30601377
[TBL] [Abstract][Full Text] [Related]
31. Vogt-Koyanagi-Harada disease-like uveitis after drug therapy including BRAF/MEK inhibitors in melanoma patients with HLA-DRB1*04.
Amagai R; Fujimura T; Yamazaki E; Takahashi M; Tamabuchi E; Kambayashi Y; Hashimoto A; Hashimoto K; Asano Y
J Dermatol; 2024 Jun; 51(6):854-857. PubMed ID: 38111371
[TBL] [Abstract][Full Text] [Related]
32. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta-analysis and systematic review.
Yu Q; Xie J; Li J; Lu Y; Liao L
Cancer Med; 2019 Sep; 8(12):5414-5424. PubMed ID: 31393083
[TBL] [Abstract][Full Text] [Related]
34. Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma.
Amann VC; Hoffmann D; Mangana J; Dummer R; Goldinger SM
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1638-1640. PubMed ID: 28401596
[TBL] [Abstract][Full Text] [Related]
35. Optimal strategy in managing advanced melanoma.
Uchi H
J Dermatol; 2024 Mar; 51(3):324-334. PubMed ID: 38087810
[TBL] [Abstract][Full Text] [Related]
36. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
37. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
Wu B; Shi L
JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
[TBL] [Abstract][Full Text] [Related]
38. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Robert C; Grob JJ; Stroyakovskiy D; Karaszewska B; Hauschild A; Levchenko E; Chiarion Sileni V; Schachter J; Garbe C; Bondarenko I; Gogas H; Mandalá M; Haanen JBAG; Lebbé C; Mackiewicz A; Rutkowski P; Nathan PD; Ribas A; Davies MA; Flaherty KT; Burgess P; Tan M; Gasal E; Voi M; Schadendorf D; Long GV
N Engl J Med; 2019 Aug; 381(7):626-636. PubMed ID: 31166680
[TBL] [Abstract][Full Text] [Related]
39. Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation.
Kiniwa Y; Nakamura K; Mikoshiba A; Ashida A; Akiyama Y; Morimoto A; Okuyama R
BMC Cancer; 2021 Mar; 21(1):287. PubMed ID: 33731038
[TBL] [Abstract][Full Text] [Related]
40. Hemorrhage of liver and bone metastases as a result of rapid response to dual BRAF/MEK inhibition in metastatic melanoma: a case report.
Loyson T; Werbrouck E; Punie K; Bonne L; Vandecaveye V; Bechter O
Melanoma Res; 2018 Apr; 28(2):147-150. PubMed ID: 29215399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]